ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $17,057.68 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 10,796 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $1.58, for a total transaction of $17,057.68. Following the completion of the sale, the insider now directly owns 580,714 shares in the company, valued at $917,528.12. This trade represents a 1.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

ALX Oncology Trading Up 16.0 %

Shares of NASDAQ ALXO opened at $1.81 on Friday. ALX Oncology Holdings Inc. has a twelve month low of $1.19 and a twelve month high of $17.83. The firm has a market cap of $95.46 million, a PE ratio of -0.61 and a beta of 1.04. The business has a fifty day simple moving average of $1.53 and a two-hundred day simple moving average of $2.82. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Institutional Trading of ALX Oncology

Hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares in the last quarter. SG Americas Securities LLC boosted its position in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of ALX Oncology in the 2nd quarter valued at $63,000. GSA Capital Partners LLP bought a new position in shares of ALX Oncology in the 3rd quarter worth $88,000. Finally, Barclays PLC lifted its stake in shares of ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after purchasing an additional 42,185 shares during the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ALXO shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $8.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.